Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, Cox AD, Der CJ.
Blake DR, et al. Among authors: huang d.
Sci Signal. 2019 Jul 16;12(590):eaav7259. doi: 10.1126/scisignal.aav7259.
Sci Signal. 2019.
PMID: 31311847
Free PMC article.